GD2-derived peptide presented in MHC (GD2-mimotope)

GD2 is a disialoganglioside highly expressed on neuroectodermal tumors, such as neuroblastoma and melanoma, but has very limited expression in normal tissues. Because carbohydrates like GD2 are typically poor immunogens and are not naturally presented by MHC molecules, researchers have developed "mimotopes"—peptides that structurally or functionally mimic the GD2 carbohydrate. These GD2-derived mimetic peptides, such as the 47-LDA sequence, can be presented by MHC class I and II molecules to activate T cells and induce IgG antibodies that cross-react with the native GD2 on tumor cells. Additionally, some evidence suggests that tumors may present naturally occurring glycopeptides (peptides with GD2-like glycans) or peptides derived from the GD2 biosynthetic enzyme, GD2 synthase (B4GALNT1), in the context of MHC. These MHC-peptide complexes serve as targets for active immunotherapy, including cancer vaccines and TCR-T cell therapies, which aim to engage the cellular immune system and generate long-lasting anti-tumor memory. Targeting this complex offers a potential strategy to overcome the limitations of traditional anti-GD2 antibodies, such as poor penetration and lack of T-cell engagement. However, safety concerns remain regarding potential neurotoxicity and the induction of autoimmunity due to the presence of GD2 on peripheral nerves.

Other names

GD2-mimotopeGD2-mimetic peptideGD2-glycopeptide47-LDA peptideGD2 synthase-derived peptideB4GALNT1-derived peptide

Induction of cross-reactive T-cell and antibody responses against GD2-expressing tumor cells through molecular mimicry or direct recognition of MHC-presented peptides.